Success Story – When Standard Treatments Fail: A Case for Virus-Specific T Cell Therapy
Key Takeaway:Virus-specific T cells (VSTs) used to successfully treat a newborn with a life-threatening CMV infectionRareKids-CAN and the Riddell Centre…
News
Read the latest from RareKids-CAN.
-
-
RareKids-CAN 2025 Conference Recap: A Celebration of Connection, Collaboration & Progress
Earlier this month, the RareKids-CAN community came together to connect, collaborate, and learn—both in person in Ottawa and virtually from…
-
Celebrating Rare Disease Day 2025
This past Rare Disease Day on February 28, 2025, our team came together to raise awareness, share patient and family…
-
Congratulations, INFORM RARE Youth Advisory Group and Dr. Lauren Kelly, for their 2024 IHDCYH Talks competition awards!
RareKids-CAN is thrilled to congratulate INFORM RARE’s Youth Advisory Group for placing first in the video category of the IHDCYH…
-
The Maternal Infant Child & Youth Research Network signs Memorandum of Understanding with the European Clinical Research Infrastructure Network
On 27 December 2024, ECRIN and MICYRN signed a Memorandum of Understanding (MoU) with the intention of better aligning their…
-
Congratulations, Maureen Smith!
RareKids-CAN is thrilled to extend our happiest congratulations to Maureen Smith on her new position on the Board of Directors…
-
Family Partner Update: Jakob and Andrea
We are happy to share an update from Andrea and her son Jakob, one of our incredible family partners on…
-
Advancing the Pediatric Clinical Trial Agenda in Ottawa
The Health Canada Relations and Advocacy Sub-Platform of RareKids-CAN and the Maternal Infant Child and Youth Research Network (MICYRN), in…
-
RareKids-CAN Co-Leads the Canadian National Mirror Group of the European Rare Diseases Research Alliance (ERDERA) Initiative
As a formal Associate Partner, RareKids-CAN and the Maternal Infant Child and Youth Research Network (MICYRN) are proud to support…
